Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population.
Jeffrey S BergerFrançois LalibertéAkshay KharatDominique LejeuneKenneth Todd MooreYoung JungPatrick LefebvreVeronica AshtonPublished in: Journal of medical economics (2021)
Rivaroxaban was associated with reduced HRU and costs compared to warfarin among NVAF patients with obesity in a real-world US setting.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- direct oral anticoagulants
- insulin resistance
- left atrial
- healthcare
- catheter ablation
- metabolic syndrome
- weight loss
- type diabetes
- left atrial appendage
- high fat diet induced
- weight gain
- venous thromboembolism
- percutaneous coronary intervention
- heart failure
- adipose tissue
- skeletal muscle
- body mass index
- left ventricular
- pulmonary embolism
- physical activity
- health information